Compare Northrop Grumman Corporation (NOC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Novo Nordisk A/S — how do they compare? Northrop Grumman Corporation trades at $478.8 (market cap $68.83B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.4× Northrop Grumman Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Novo Nordisk A/S for 116 Days on average.
| NOC | NVO | |
|---|---|---|
Market Cap | $68.83B | $165.31B |
Volume | 1,081,989 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $768.02 | $63.98 |
52-Week Low | $473.46 | $35.29 |
Typical Hold Time | 81 Days | 116 Days |
Enterprise Value | $82.81B | $179.56B |
Dividend Yield | 2.04% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $480.85, up 1.56% with recent earnings beats but faces technical bearish signals. The company maintains strong fundamentals with $41.95B revenue, 10.48% net margin, and attractive valuation at 15.4 P/E. Recent news highlights both contract wins and competitive losses, including Boeing's $20B Navy fighter award.
Outlook remains positive with analyst consensus at $600.62 target (25% upside) and 54% buy ratings. Key risks include defense contract volatility and competitive pressures, while strong backlog ($104.7B) and dividend growth support long-term value. The stock offers defensive exposure to elevated defense spending cycles.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
